杭州科霖诺科技有限公司

Company Overview:
ClinActiv is a newly established China-to-global dermatology consumer health platform, leveraging collagen-based late-stage assets, global M&A biomaterial R&D to build a global footprint from day one. With the founder’s proven track record strategic resources, ClinActiv aims to grow a Galderma-scale dermatology leader, powered by innovation cash-generating acquisitions.

Assets growth drivers
China Collagen Pipeline: Bovine, recombinant, triple-helix collagen assets, several already at NDA filing near-approval stage, with key applications in skin care, injectable aesthetics wound repair.
Scarce animal-derived collagen capacity as initial edge: ClinActiv controls ~20kg/year; by comparison, leading competitsustains ~RMB 300m revenue with only 5kg, highlighting ClinActiv’s rare highly differentiated entry point.
North America Expansion via clear M&A target: Acquisition in progress of a long-term partner with established brands, CDMO infrastructure commercial coverage, providing immediate global footprint cash flow.
R&D Ecosystem: Partnering with leading academic institutions to drive biomaterial innovation sustain next-generation skincare pipelines.

Founder track record
Entrepreneurship: A successful serial entrepreneur with a history of building scaling ventures across consumer health life sciences.
Strategic Background: Largest shareholder of Waldencast (NASDAQ: WALD), which owns Obagi, one of the most iconic global skincare brands, while also retaining direct ownership of Obagi China. Brings deep expertise across skincare, consumer healthcare management, global M&A, international operations, backed by a strong global network.

Investbacking
Incubated by Hongshan (ex-Sequoia China) supported by Hillhouse, demonstrating strong confidence in ClinActiv’s model.